---
title: "Ascentage Pharma Group International (AAPG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AAPG.US.md"
symbol: "AAPG.US"
name: "Ascentage Pharma Group International"
industry: "Biotechnology"
datetime: "2026-03-03T12:11:20.258Z"
locales:
  - [en](https://longbridge.com/en/quote/AAPG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AAPG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AAPG.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AAPG.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AAPG.US.md)


# Ascentage Pharma Group International (AAPG.US)

## Company Overview

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ascentage.cn](https://www.ascentage.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:16.000Z

**Overall: E (0.83)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 376 / 405 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -56.53% |  |
| Net Profit YoY | -223.38% |  |
| P/B Ratio | 23.78 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2208197382.30 |  |
| Revenue | 54367001.09 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -161.85% | E |
| Profit Margin | -296.77% | E |
| Gross Margin | 90.74% | A |
| Revenue YoY | -56.53% | E |
| Net Profit YoY | -223.38% | E |
| Total Assets YoY | -0.66% | D |
| Net Assets YoY | -11.79% | E |
| Cash Flow Margin | -33.70% | D |
| OCF YoY | -56.53% | E |
| Turnover | 0.13 | E |
| Gearing Ratio | 77.81% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ascentage Pharma Group International",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-56.53%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-223.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "23.78",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2208197382.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "54367001.09",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-161.85%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-296.77%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "90.74%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-56.53%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-223.38%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.66%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-11.79%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-33.70%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-56.53%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "77.81%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.69 | 478/405 | - | - | - |
| PB | 23.78 | 414/405 | 70.43 | 38.38 | 26.33 |
| PS (TTM) | 40.62 | 226/405 | 56.56 | 40.89 | 15.81 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | OpGen (OPGN.US) | B | A | A | A | B | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.66 |
| Highest Target | 55.00 |
| Lowest Target | 45.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AAPG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AAPG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AAPG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AAPG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**